Mulberroside A from Cortex Mori Enhanced Gut Integrity in Diabetes

Area of Science:

• Metabolic diseases
• Gut microbiome research
• Pharmacognosy

Background:

• Diabetic endotoxemia is a key feature of type 2 diabetes mellitus (T2DM).
• Gut leak is increasingly recognized as a significant contributor to diabetic endotoxemia.
• Cortex Mori (CM) is traditionally used for T2DM, but its impact on endotoxemia is not well understood.

Purpose of the Study:

• To investigate the effects of Cortex Mori (CM) on diabetic endotoxemia in a mouse model.
• To explore the efficacy of mulberroside A (MBA), an active component of CM, in combating diabetic endotoxemia.
• To elucidate the underlying mechanisms by which MBA ameliorates diabetic endotoxemia.

Main Methods:

• In vivo study using db/db mice treated with CM water extract, with C57BL/6 mice as normal controls.
• In vitro study assessing the effects of mulberroside A (MBA) on lipopolysaccharide (LPS)-induced endotoxemia.
• Analysis of blood glucose, liver and renal damage, gut integrity (ICAM-1 expression), oxidative stress markers (MDA, ROS), and epithelial barrier function.

Main Results:

• CM water extract significantly reduced blood glucose, liver/renal damage, and diabetic endotoxemia in db/db mice (p < 0.01).
• CM treatment enhanced gut integrity and decreased ICAM-1 expression.
• MBA decreased LPS-induced MDA and ROS levels (p < 0.01) and improved gut epithelial barrier function (p < 0.01).

Conclusions:

• Cortex Mori and its active component mulberroside A demonstrate a therapeutic potential for ameliorating diabetic endotoxemia.
• Preservation of gut integrity is identified as a key mechanism through which CM and MBA exert their beneficial effects.
• These findings suggest CM as a promising natural intervention for managing T2DM-related complications.